Blood Cancer Talks

In this episode, we delve into the weeds of bispecific antibodies across lymphomas with Dr. Michael Dickinson from Peter MacCallum Cancer Center, Melbourne, Australia. Here are the key articles we discussed: 

1. Glofitamab for Relapsed/Refractory DLBCL:
2. Long-term follow-up data on blinatumomab in relapsed/refractory B-cell NHL:
3. Phase 1/2 study of epcoritamab in relapsed/refractory DLBCL:
4. Phase 2 trial of mosunetuzumab in relapsed/refractory follicular lymphoma:
5. Phase 1 trial of odronextamab in relapsed/refractory B-cell NHL:
6. Epcoritamab + R2 in high-risk follicular lymphoma:
7. Glofitamab in Mantle Cell Lymphoma:

What is Blood Cancer Talks?

This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth.
Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston
Tweet your suggestions and feedback to @rajshekharucms @AshKishtagari @Eddie_Cliff @BloodCancerTalk